Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Maruho Taps Meiji as Copromotion Partner for Amenalief
October 9, 2020
- Towa Plans to Start Full-Scale Continuous Manufacturing in FY2024, Aiming at Whole Automated Process
October 9, 2020
- University of Tokyo, Eisai Link Arms for Research on Targeted Protein Degradation Technology
October 9, 2020
- AnGes Out-Licenses Collategene to Turkish Pharma
October 9, 2020
- Sumitomo Dainippon Rejigs Organization to Become Top CNS Player in Japan, Sets 50 Billion Yen Near-Term Goal
October 8, 2020
- Japan Ethical Drug Sales Dip 9.0% in August: Crecon
October 8, 2020
- Pfizer, Merck Biopharma to End Xalkori Copromotion in Japan
October 8, 2020
- Fujifilm to Expand Viral Vector CDMO Biz to Europe
October 8, 2020
- Hisamitsu Initiates Japan PIII of Palmar Hyperhidrosis Drug, Aims at Filing in FY2022
October 8, 2020
- 1 More Soft Bag Product Recalled Over Flawed Testing at Kyowa CritiCare
October 8, 2020
- HUYA Files Novel T-Cell Leukemia-Lymphoma Med in Japan
October 8, 2020
- Pfizer Renames Japan Subsidiaries as Mylan Deal Set to Close Soon; Upjohn Biz Now Separate
October 7, 2020
- Keytruda Top Selling Drug in September: Encise
October 7, 2020
- Eisai, 4 Research Organizations Begin Collaborative Project for COVID-19 Treatments
October 7, 2020
- Sunovion’s Apomorphine Sublingual Hits US Market
October 7, 2020
- Chugai Licenses Antibody Engineering Tech to argenx
October 7, 2020
- Armed with Enerzair, Novartis Looks to Establish Leading Position in Respiratory Arena
October 6, 2020
- Crysvita Approved in Europe for Adult XLH: Kyowa Kirin
October 6, 2020
- Nihon Chouzai’s Standard Formulary Service Fully Up and Running
October 5, 2020
- Axcelead, Kyowa Kirin Join Forces to Develop Small-Molecule Drugs
October 5, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…